Retatrutide 20mg

The triple agonist. One of the most discussed compounds in metabolic research over the last two years — and our best-selling product, for reasons the Phase 2 clinical data made fairly obvious.

Retatrutide targets GLP-1, GIP, and glucagon receptors simultaneously, making it mechanistically distinct from earlier single-agonist compounds. It's the subject of significant ongoing clinical and pre-clinical research across multiple therapeutic areas.

Research has examined Retatrutide in the context of:

• GLP-1 receptor pathway activation and appetite regulation models
• GIP receptor modulation and metabolic balance
• Glucagon receptor effects on energy expenditure
• Adiposity and body composition research
• Lipid metabolism and cardiometabolic risk factor studies

20mg per vial. Our top seller — the clinical literature is unusually strong for a compound still in active development.

Supplied: Lyophilised powder, ≥99% purity, third-party tested. CoA available on request.
Storage: Refrigerate at 2–8°C. Reconstitute with bacteriostatic water. Use within 45 days of reconstitution.
For research use only. Not for human consumption. Not for sale to minors.